NZ582459A - Antimicrobial peptide, compositions, and methods of use - Google Patents

Antimicrobial peptide, compositions, and methods of use

Info

Publication number
NZ582459A
NZ582459A NZ582459A NZ58245908A NZ582459A NZ 582459 A NZ582459 A NZ 582459A NZ 582459 A NZ582459 A NZ 582459A NZ 58245908 A NZ58245908 A NZ 58245908A NZ 582459 A NZ582459 A NZ 582459A
Authority
NZ
New Zealand
Prior art keywords
composition
composition according
arg
kit
peptide
Prior art date
Application number
NZ582459A
Other languages
English (en)
Inventor
Hongran Fan Stone
Jacob M Waugh
Original Assignee
Revance Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Revance Therapeutics Inc filed Critical Revance Therapeutics Inc
Publication of NZ582459A publication Critical patent/NZ582459A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0063—Periodont
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005—Antimicrobial preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Birds (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
NZ582459A 2007-07-26 2008-07-28 Antimicrobial peptide, compositions, and methods of use NZ582459A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95205907P 2007-07-26 2007-07-26
PCT/US2008/071350 WO2009015385A1 (en) 2007-07-26 2008-07-28 Antimicrobial peptide, compositions , and methods of use

Publications (1)

Publication Number Publication Date
NZ582459A true NZ582459A (en) 2012-05-25

Family

ID=40281862

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ582459A NZ582459A (en) 2007-07-26 2008-07-28 Antimicrobial peptide, compositions, and methods of use

Country Status (24)

Country Link
US (1) US8623811B2 (cg-RX-API-DMAC7.html)
EP (3) EP3741380A1 (cg-RX-API-DMAC7.html)
JP (5) JP5401457B2 (cg-RX-API-DMAC7.html)
KR (4) KR101722038B1 (cg-RX-API-DMAC7.html)
CN (2) CN102872447B (cg-RX-API-DMAC7.html)
AU (1) AU2008278593B2 (cg-RX-API-DMAC7.html)
BR (3) BRPI0813627B1 (cg-RX-API-DMAC7.html)
CA (1) CA2694046C (cg-RX-API-DMAC7.html)
CO (1) CO6260098A2 (cg-RX-API-DMAC7.html)
CR (1) CR11239A (cg-RX-API-DMAC7.html)
CY (2) CY1118503T1 (cg-RX-API-DMAC7.html)
DK (2) DK3120862T3 (cg-RX-API-DMAC7.html)
ES (2) ES2609914T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20161722T1 (cg-RX-API-DMAC7.html)
HU (1) HUE031136T2 (cg-RX-API-DMAC7.html)
IL (3) IL203173A (cg-RX-API-DMAC7.html)
LT (1) LT2178549T (cg-RX-API-DMAC7.html)
MX (1) MX2010000916A (cg-RX-API-DMAC7.html)
NZ (1) NZ582459A (cg-RX-API-DMAC7.html)
PL (1) PL2178549T3 (cg-RX-API-DMAC7.html)
PT (2) PT2178549T (cg-RX-API-DMAC7.html)
SG (1) SG188128A1 (cg-RX-API-DMAC7.html)
SI (1) SI2178549T1 (cg-RX-API-DMAC7.html)
WO (1) WO2009015385A1 (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2109363A4 (en) * 2006-12-29 2014-07-09 Revance Therapeutics Inc TRANSPORTING MOLECULES WITH REVERSE SEQUENCE HIV TAT POLYPEPTIDES
EP3741380A1 (en) * 2007-07-26 2020-11-25 ReVance Therapeutics, Inc. Antimicrobial peptide and compositions thereof
US8080518B2 (en) * 2007-12-05 2011-12-20 Arbor Vita Corporation Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
DK3031825T3 (da) 2008-03-14 2019-10-28 Allergan Inc Immunbaserede aktivitetsassays for botulinum-toxin serotype a
KR102005930B1 (ko) 2008-12-31 2019-07-31 레반스 테라퓨틱스, 아이엔씨. 주사용 보툴리눔 독소 제제
PT2413947T (pt) * 2009-04-01 2020-05-28 Revance Therapeutics Inc Métodos e composições para tratar condições de pele associadas à hiper-reatividade vascular
PT2440231T (pt) 2009-06-10 2020-01-08 Nono Inc Co-administração de um agente ligado a um peptido de internalização tat com um inibidor de desgranulação de mastócitos
CA2766521C (en) * 2009-06-25 2020-07-21 Revance Therapeutics, Inc. Albumin-free botulinum toxin formulations
US8387798B1 (en) 2012-04-27 2013-03-05 Abdulmohsen E. A. H. Al-Terki Mutiple oral and nasal surgical procedures method and kit
US10022083B2 (en) 2011-06-02 2018-07-17 Abdulmohsen E. A. H. Al-Terki Multiple oral and nasal surgical procedures method and kit
FR2997304B1 (fr) 2012-10-26 2017-07-07 Isp Investments Inc Utilisation d’un extrait de lin, en tant qu’agent actif activateur de la synthese de peptides antimicrobiens
CA2889833A1 (en) 2012-10-28 2014-05-01 Revance Therapeutics, Inc. Compositions and methods for safe treatment of rhinitis
US20140242110A1 (en) * 2013-02-28 2014-08-28 Dt Scimed, Llc Dose, localization, and formulation of botulinum toxins in skin and muscle
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US11446236B2 (en) 2015-08-05 2022-09-20 Cmpd Licensing, Llc Topical antimicrobial compositions and methods of formulating the same
US11684567B2 (en) 2015-08-05 2023-06-27 Cmpd Licensing, Llc Compositions and methods for treating an infection
US11793783B2 (en) 2015-08-05 2023-10-24 Cmpd Licensing, Llc Compositions and methods for treating an infection
US10744189B2 (en) * 2015-09-17 2020-08-18 Contrafect Corporation Lysin polypeptides active against Gram-negative bacteria
US10105381B2 (en) * 2016-05-23 2018-10-23 Cmpd Licensing, Llc Compositions and methods for treating an infection
US10144767B2 (en) * 2016-08-18 2018-12-04 Board Of Regents Of The University Of Nebraska Anti-microbial peptides and coatings
AU2017360346B2 (en) * 2016-11-21 2023-11-23 Eirion Therapeutics, Inc. Transdermal delivery of large agents
WO2019046311A1 (en) 2017-08-28 2019-03-07 Revance Therapeutics, Inc. TRANSMUCOSAL COMPOSITIONS OF BOTULINUM TOXIN, KITS AND METHODS FOR TREATING BLADDER DISORDERS
CN107556374B (zh) * 2017-08-30 2020-02-07 四川大学 唾液富脯蛋白仿生防龋功能多肽、其衍生物和盐及其应用
CN107353334B (zh) * 2017-08-30 2020-02-07 四川大学 基于唾液富酪蛋白的仿生防龋多肽、其衍生物和盐及应用
JP7266202B2 (ja) * 2018-02-19 2023-04-28 株式会社ファンケル 化粧料及び抗炎症剤
JP2023521796A (ja) * 2020-04-08 2023-05-25 アミクローブ，インコーポレイテッド ウイルス感染症の予防及び治療のために局所投与される合成アミノ酸ポリマーの組成物及びその使用
WO2025059665A1 (en) 2023-09-15 2025-03-20 Revance Therapeutics, Inc. Serial treatment with botulinum toxin for cervical dystonia
WO2025064729A1 (en) 2023-09-19 2025-03-27 Revance Therapeutics, Inc. Treatment with botulinum toxin in patients in need of a rapid onset cosmetic effect and smoother skin appearance
WO2025072381A1 (en) 2023-09-25 2025-04-03 Revance Therapeutics, Inc. Methods for determining influence of carrier peptide on the binding of a therapeutic protein to a cell membrane

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744166A (en) 1989-02-25 1998-04-28 Danbiosyst Uk Limited Drug delivery compositions
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US5674980A (en) 1989-12-21 1997-10-07 Biogen Inc Fusion protein comprising tat-derived transport moiety
EP0637247B1 (en) * 1992-04-23 1998-08-19 Allelix Biopharmaceuticals Inc. Treatment of herpesvirus infection
ATE173016T1 (de) 1992-08-21 1998-11-15 Biogen Inc Von tat abgeleitete transportpolypeptide
WO1995011038A1 (en) * 1993-10-22 1995-04-27 Allelix Biopharmaceuticals Inc. Treatment of cytomegalovirus infection
CA2180011C (en) 1993-12-28 2001-05-15 K. Roger Aoki Botulinum toxins for treating sweating
US6232295B1 (en) 1994-10-12 2001-05-15 Jon Faiz Kayyem Cell-specific contrast agent and gene delivery vehicles
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
ATE412668T1 (de) 1995-08-23 2008-11-15 Univ British Columbia Antimikrobielle kationische peptide und methoden zu ihrer identifizierung
US6043218A (en) * 1996-10-22 2000-03-28 Medical University Of South Carolina Positively charged non-natural amino acids, methods of making thereof, and use thereof in peptides
GB9623051D0 (en) 1996-11-06 1997-01-08 Schacht Etienne H Delivery of DNA to target cells in biological systems
AU1818299A (en) 1997-12-10 1999-06-28 Washington University Anti-pathogen system and methods of use thereof
WO1999031261A1 (en) 1997-12-12 1999-06-24 Onyx Pharmaceuticals, Inc. SELECTIVE KILLING AND DIAGNOSIS OF p53+ NEOPLASTIC CELLS
AU1706400A (en) 1998-10-27 2000-05-15 Mayo Foundation For Medical Education And Research Methods for enhancing wound healing
WO2000034308A2 (en) 1998-12-10 2000-06-15 Washington University Protein transduction system and methods of use thereof
TR200101790T2 (tr) 1998-12-23 2001-10-22 Idea Ag. Yayılgan olmayan in vivo topik uygulamalar için geliştirilmiş formül
US7056656B1 (en) 1999-01-25 2006-06-06 University Of Medicine And Dentistry Of New Jersey Tat-derived oligourea and its method of production and use in high affinity and specific binding HIV-1 TAR RNA
US20030236214A1 (en) 1999-06-09 2003-12-25 Wolff Jon A. Charge reversal of polyion complexes and treatment of peripheral occlusive disease
US7008924B1 (en) 1999-07-21 2006-03-07 Amgen, Inc. VGF fusion polypeptides
US6669951B2 (en) 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US6544548B1 (en) 1999-09-13 2003-04-08 Keraplast Technologies, Ltd. Keratin-based powders and hydrogel for pharmaceutical applications
US6844324B1 (en) 1999-11-12 2005-01-18 Massachusetts Institute Of Technology Modular peptide mediated intracellular delivery system and uses therefore
US20030118598A1 (en) 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US6670322B2 (en) 2000-06-01 2003-12-30 Wisconsin Alumni Research Foundation Method of targeting pharmaceuticals to motor neurons
US20040220100A1 (en) 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
AU8466501A (en) 2000-07-21 2002-02-05 Essentia Biosystems Inc Multi-component biological transport systems
US20030215412A1 (en) 2000-07-21 2003-11-20 Essentia Biosystems, Inc. Induction of hair growth with vascular endothelial growth factor
US6696038B1 (en) 2000-09-14 2004-02-24 Expression Genetics, Inc. Cationic lipopolymer as biocompatible gene delivery agent
US20020127247A1 (en) 2000-11-17 2002-09-12 Allergen Sales, Inc. Modified clostridial neurotoxins with altered biological persistence
WO2002065986A2 (en) 2001-02-16 2002-08-29 Cellgate, Inc. Transporters comprising spaced arginine moieties
WO2002090520A2 (en) * 2001-05-09 2002-11-14 Yale University Toll/interleukin-1 receptor adaptor protein (tirap)
US7060498B1 (en) 2001-11-28 2006-06-13 Genta Salus Llc Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
JP2005538035A (ja) 2001-12-11 2005-12-15 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ グアニジニウム輸送試薬および結合体
WO2003072049A2 (en) 2002-02-21 2003-09-04 Essentia Biosystems, Inc. Induction of hair growth with vascular endothelial growth factor
US20030215395A1 (en) 2002-05-14 2003-11-20 Lei Yu Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier
US20040009180A1 (en) 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
JP4154218B2 (ja) * 2002-11-27 2008-09-24 寛紀 高麗 新規抗菌性ポリペプチドとその利用
IL153557A0 (en) * 2002-12-19 2003-07-06 Yitzchak Hillman Antibodies and antagonists to antimicrobial peptides for the purpose of treating, inhibiting and preventing auto immune diseases
JP2006514106A (ja) * 2002-12-19 2006-04-27 ヒルマン，イチャク 抗菌ペプチド阻害剤による疾患治療
JP2006516639A (ja) * 2003-02-01 2006-07-06 ニユーララブ・リミテツド 可溶性Ａ−βに対する抗体を生成させるための能動免疫
WO2004084805A2 (en) 2003-03-19 2004-10-07 The J. David Gladstone Institutes Acetylated tat polypeptides and methods of use thereof
US7125842B2 (en) * 2003-04-07 2006-10-24 Canbas Co. Ltd. Anti-fungal compounds and methods of use
KR20070033314A (ko) * 2003-09-12 2007-03-26 더 유니버시티 오브 브리티쉬 콜럼비아 양이온성 펩티드를 사용한 선천 면역의 자극 방법
JP2005120050A (ja) * 2003-10-20 2005-05-12 Toagosei Co Ltd 新規抗菌性ペプチドとその利用
WO2005120546A2 (en) 2004-03-03 2005-12-22 Essentia Biosystems, Inc. Compositions and methods for topical diagnostic and therapeutic transport
US8404249B2 (en) 2004-03-03 2013-03-26 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
EP3141559A1 (en) * 2004-08-18 2017-03-15 Novabiotics Limited Antimicrobial peptides
EP1656951A1 (en) * 2004-11-12 2006-05-17 Xigen S.A. Conjugates with enhanced cell uptake activity
US20080207522A1 (en) 2004-11-12 2008-08-28 Hancock Robert E W Antimicrobial Peptides
EP1661912A1 (en) 2004-11-29 2006-05-31 Xigen S.A. Fusion protein comprising a BH3-domain of a BH3-only protein
JP4730584B2 (ja) * 2004-12-06 2011-07-20 東亞合成株式会社 抗菌ペプチド及びその利用
JP2006238751A (ja) * 2005-03-02 2006-09-14 Toagosei Co Ltd ベロ毒素結合性を有する抗菌ペプチド及びその利用
US9180081B2 (en) 2005-03-03 2015-11-10 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
ZA200707351B (en) 2005-03-03 2010-02-24 Revance Therapeutics Inc Compositions and methods for topical application and transdermal delivery of an oligopeptide
KR20080006568A (ko) 2005-03-30 2008-01-16 레반스 테라퓨틱스, 아이엔씨. 여드름 치료용 조성물 및 방법
NZ568216A (en) 2005-11-17 2012-09-28 Revance Therapeutics Inc Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins
BRPI0720730A2 (pt) 2006-12-29 2014-04-08 Revance Therapeutics Inc Composições e métodos de aplicação tópica e liberação transdérmica de toxinas botulínicas estabilizadas com fragmentos de polipeptídeo derivados de hiv-tat.
EP2109363A4 (en) 2006-12-29 2014-07-09 Revance Therapeutics Inc TRANSPORTING MOLECULES WITH REVERSE SEQUENCE HIV TAT POLYPEPTIDES
EP3741380A1 (en) * 2007-07-26 2020-11-25 ReVance Therapeutics, Inc. Antimicrobial peptide and compositions thereof
KR102005930B1 (ko) 2008-12-31 2019-07-31 레반스 테라퓨틱스, 아이엔씨. 주사용 보툴리눔 독소 제제

Also Published As

Publication number Publication date
IL223785A (en) 2015-02-26
BR122019000258B1 (pt) 2021-09-14
HK1180237A1 (zh) 2013-10-18
SG188128A1 (en) 2013-03-28
KR101722038B1 (ko) 2017-04-03
KR20150090268A (ko) 2015-08-05
KR20170016031A (ko) 2017-02-10
KR101717275B1 (ko) 2017-03-16
CY1123176T1 (el) 2021-10-29
IL223784A (en) 2015-02-26
CN101842107B (zh) 2014-04-23
US20100215591A1 (en) 2010-08-26
JP6722241B2 (ja) 2020-07-15
AU2008278593A2 (en) 2011-05-12
JP2019006791A (ja) 2019-01-17
CR11239A (es) 2010-06-29
PL2178549T3 (pl) 2017-03-31
CN101842107A (zh) 2010-09-22
PT3120862T (pt) 2020-06-25
DK3120862T3 (da) 2020-06-22
AU2008278593B2 (en) 2015-04-09
IL203173A (en) 2014-12-31
BRPI0813627A2 (pt) 2014-12-23
US8623811B2 (en) 2014-01-07
BR122019000266B1 (pt) 2021-09-14
ES2609914T3 (es) 2017-04-25
EP3120862B1 (en) 2020-04-29
EP2178549A4 (en) 2014-02-19
JP2010534684A (ja) 2010-11-11
JP2014076993A (ja) 2014-05-01
CY1118503T1 (el) 2017-07-12
EP2178549B1 (en) 2016-09-14
KR102088949B1 (ko) 2020-03-13
KR20100047867A (ko) 2010-05-10
LT2178549T (lt) 2017-01-25
JP2020169190A (ja) 2020-10-15
CN102872447A (zh) 2013-01-16
HUE031136T2 (en) 2017-07-28
SI2178549T1 (sl) 2017-08-31
CO6260098A2 (es) 2011-03-22
WO2009015385A1 (en) 2009-01-29
ES2805225T3 (es) 2021-02-11
JP5401457B2 (ja) 2014-01-29
CA2694046C (en) 2023-09-12
EP3741380A1 (en) 2020-11-25
HRP20161722T1 (hr) 2017-02-10
EP3120862A1 (en) 2017-01-25
JP2017002057A (ja) 2017-01-05
CA2694046A1 (en) 2009-01-29
BRPI0813627B1 (pt) 2021-09-14
KR20180031824A (ko) 2018-03-28
DK2178549T3 (en) 2017-01-09
CN102872447B (zh) 2015-09-30
PT2178549T (pt) 2016-12-20
AU2008278593A1 (en) 2009-01-29
EP2178549A1 (en) 2010-04-28
MX2010000916A (es) 2010-06-02
JP5965884B2 (ja) 2016-08-10

Similar Documents

Publication Publication Date Title
CA2694046C (en) Cationic peptides and compositions thereof
ES2958621T3 (es) Composiciones para el tratamiento tópico de infecciones microbianas
US20240325335A1 (en) Biologically compatible, biofilm disrupting composition and methods
JP2015516943A (ja) ポリペプチド及びその使用
HK40040748A (en) Antimicrobial peptide and compositions thereof
HK1180237B (en) Antimicrobial peptide, compositions, and methods of use
HK1147424B (en) Antimicrobial peptide, compositions, and methods of use
HK1147424A (en) Antimicrobial peptide, compositions, and methods of use
US20250352515A1 (en) Topical formulations

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JUL 2016 BY CPA GLOBAL

Effective date: 20150724

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JUL 2017 BY CPA GLOBAL

Effective date: 20160701

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JUL 2018 BY CPA GLOBAL

Effective date: 20170713

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JUL 2019 BY CPA GLOBAL

Effective date: 20180614

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JUL 2020 BY CPA GLOBAL

Effective date: 20190704

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JUL 2021 BY THOMSON REUTERS

Effective date: 20200721

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JUL 2022 BY THOMSON REUTERS

Effective date: 20210604

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JUL 2023 BY THOMSON REUTERS

Effective date: 20220603

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JUL 2024 BY THOMSON REUTERS

Effective date: 20230703

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JUL 2025 BY THOMSON REUTERS

Effective date: 20240725

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JUL 2026 BY THOMSON REUTERS

Effective date: 20250725